Abstract
The review examines the state of the art of diagnosis and therapy of high-grade gliomas both by currently existing clinical guidelines, and from the point of view of the most promising approaches of currently undergoing laboratory tests and the first clinical trials. One of the most promising approach for the treatment of malignant gliomas is the nonpathogenic oncolytic viruses (OV) application. The data of preclinical trials of OV and the first preliminary results of clinical trials are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
